Cargando…
The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
Radiotherapy (RT) is a standard treatment strategy for many cancer types, but the need to frequently apply high doses of ionizing radiation in order to achieve therapeutic efficacy can cause severe harm to healthy tissues, leading to adverse patient outcomes. In an effort to minimize these toxic sid...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387205/ https://www.ncbi.nlm.nih.gov/pubmed/34458237 http://dx.doi.org/10.3389/fchem.2021.710250 |
_version_ | 1783742413767966720 |
---|---|
author | Sun, Xiurong Su, Fangming Luo, Xin Ning, Yingxia |
author_facet | Sun, Xiurong Su, Fangming Luo, Xin Ning, Yingxia |
author_sort | Sun, Xiurong |
collection | PubMed |
description | Radiotherapy (RT) is a standard treatment strategy for many cancer types, but the need to frequently apply high doses of ionizing radiation in order to achieve therapeutic efficacy can cause severe harm to healthy tissues, leading to adverse patient outcomes. In an effort to minimize these toxic side effects, we herein sought to design a novel approach to the low-dose RT treatment of hypoxic tumors using a Tirapazamine (TPZ)-loaded exosome (EXO) nanoplatform (MT). This MT platform was synthesized via loading EXOs with TPZ, which is a prodrug that is activated when exposed to hypoxic conditions. MT application was able to achieve effective tumor inhibition at a relatively low RT dose (2 Gy) that was superior to standard high-dose (6 Gy) RT treatment with specific targeting to the hypoxic region of tumor. RT-mediated oxygen consumption further aggravated hypoxic conditions to improve TPZ activation and treatment efficacy. Together, our findings demonstrate the clinical promise of this MT platform as a novel tool for the efficient radiosensitization and treatment of cancer patients. |
format | Online Article Text |
id | pubmed-8387205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83872052021-08-26 The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy Sun, Xiurong Su, Fangming Luo, Xin Ning, Yingxia Front Chem Chemistry Radiotherapy (RT) is a standard treatment strategy for many cancer types, but the need to frequently apply high doses of ionizing radiation in order to achieve therapeutic efficacy can cause severe harm to healthy tissues, leading to adverse patient outcomes. In an effort to minimize these toxic side effects, we herein sought to design a novel approach to the low-dose RT treatment of hypoxic tumors using a Tirapazamine (TPZ)-loaded exosome (EXO) nanoplatform (MT). This MT platform was synthesized via loading EXOs with TPZ, which is a prodrug that is activated when exposed to hypoxic conditions. MT application was able to achieve effective tumor inhibition at a relatively low RT dose (2 Gy) that was superior to standard high-dose (6 Gy) RT treatment with specific targeting to the hypoxic region of tumor. RT-mediated oxygen consumption further aggravated hypoxic conditions to improve TPZ activation and treatment efficacy. Together, our findings demonstrate the clinical promise of this MT platform as a novel tool for the efficient radiosensitization and treatment of cancer patients. Frontiers Media S.A. 2021-08-11 /pmc/articles/PMC8387205/ /pubmed/34458237 http://dx.doi.org/10.3389/fchem.2021.710250 Text en Copyright © 2021 Sun, Su, Luo and Ning. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Sun, Xiurong Su, Fangming Luo, Xin Ning, Yingxia The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy |
title | The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy |
title_full | The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy |
title_fullStr | The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy |
title_full_unstemmed | The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy |
title_short | The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy |
title_sort | use of bionic prodrugs for the enhancement of low dose radiotherapy |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387205/ https://www.ncbi.nlm.nih.gov/pubmed/34458237 http://dx.doi.org/10.3389/fchem.2021.710250 |
work_keys_str_mv | AT sunxiurong theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy AT sufangming theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy AT luoxin theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy AT ningyingxia theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy AT sunxiurong useofbionicprodrugsfortheenhancementoflowdoseradiotherapy AT sufangming useofbionicprodrugsfortheenhancementoflowdoseradiotherapy AT luoxin useofbionicprodrugsfortheenhancementoflowdoseradiotherapy AT ningyingxia useofbionicprodrugsfortheenhancementoflowdoseradiotherapy |